Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SillaJen, Inc. (215600.KQ)
KRW2,120.00
+90.00 (+4.43%)
KR KOE Healthcare Biotechnology
Address
O2 Tower 7325
Seoul, KR
Seoul, KR
CEO
Jaekyung Kim
Website
sillajen.com
IPO
2016-12-06
ISIN KR7215600008
Description
SillaJen, Inc. is dedicated to the advancement and commercialization of oncolytic immunotherapy products. Its primary therapeutic candidate, Pexa-Vec, is currently undergoing Phase II clinical evaluation as a potential treatment for late-stage liver cancer. The firm also has JX-970 in development, aimed at targeting tumor tissues, and the JX-900 series, which consists of modified vaccinia vaccines. Established in 2006, SillaJen is headquartered in Seoul, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW2,120.00
+90.00 (+4.43%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
912.8K
Beta
-0.05
Float Shares
119.41M
Free Float %
86.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.45% | +7.49% | -9.71% | -11.53% | +22.68% | -5.98% | +3.29% | -44.29% | -67.14% | -72.25% | -72.25% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2,120.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
35.94
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+134.9% ★ Q1'26: +146.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+20.0% Q1'26: +1.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-291.4% Q1'26: -166.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-276.5% Q1'26: +100.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-71.7% Q1'26: +32.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+13.3% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.09× Q1'26: -0.10× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
|---|---|---|---|
| Revenue |
7.71B
est: 8.90M (+86,552.0%)
|
9.07B
est: 9.30M (+97,411.6%)
|
1.67B
est: 9.80M (+16,937.9%)
|
| EBITDA |
-51.38B
est: -8.90M (-577,214.7%)
|
-104.40B
est: -9.30M (-1,122,504.1%)
|
-44.42B
est: -9.80M (-453,176.1%)
|
| EBIT |
-54.92B
est: -8.90M (-616,979.8%)
|
-107.75B
est: -9.30M (-1,158,461.9%)
|
-46.15B
est: -9.80M (-470,804.8%)
|
| Net Income |
-56.24B
|
-113.20B
|
-47.82B
|
| SGA |
42.10B
est: 113.51M (+36,989.7%)
|
42.28B
est: 118.62M (+35,540.4%)
|
25.03B
est: 124.99M (+19,926.6%)
|
| EPS |
-737.49
|
-1,481.28
|
-618.29
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-23.57B
OE per share TTM
-171.47
Owner's Yield
-5.17%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
49.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 5 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex Healthcare 266420.KS | 0.24% | 107.0K | 0.09% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 80.7K | 0.28% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 57.2K | 0.39% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 23.1K | 0.29% |
| 5 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 311.69 | 0.33% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-5.93M
Shares Outstanding
138.13M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chan Kwon Hyuk | Chief Medical Officer | — | — |
| Eun-Ki Min | Chief Accounting Officer and Executive Director | — | male |
| Jaejeong Lee | Executive Officer | — | male |
| Jaekyung Kim | Chief Executive Officer & Chairman of the Board | — | male |
| Jeongseok Lee | Executive Officer | — | male |
| Mee Yang Kyung | Head of R&D Strategic Planning | — | — |
| SangGeun Park | Executive Director | — | male |
| SeungHwan Cho | Executive Officer | — | male |
| Suk Song Myung | Chief Financial Officer | — | — |
| TaeGyun Kim | President | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 215600.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
